🎗️ Tamoxifen vs Aromatase Inhibitor Side-Effect Comparator

Two Effective Options, Two Different Risk Profiles

Placeholder: both hormone therapies work well but harm differently.

• 5–10 yrs: Treatment duration (placeholder text)
• 2: Therapy class count (SERM vs AI)
• ~70%: ER+ cancers (placeholder text)
• Multiple: Decision drivers (placeholder text)

Why the choice matters

Placeholder: efficacy is similar, side effects diverge over years of use.

Partial Agonism Drives Uterine and Clotting Risk

Placeholder: tamoxifen acts as estrogen agonist in the uterus and clotting cascade.

• ~2–3×: Endometrial cancer RR (placeholder text)
• ~2×: VTE risk increase (placeholder text)
• SERM: Mechanism (partial agonist)
• Years 2–5: Peak risk window (placeholder text)

Endometrial effect

Placeholder: agonist action thickens uterine lining over time.

Clotting factor effect

Placeholder: estrogen-like effect on clotting factors raises thromboembolism risk.

Placeholder: clot and endometrial risk rise steadily with years on drug.

Estrogen Suppression Drives Bone and Joint Risk

Placeholder: AIs suppress estrogen almost completely, unlike tamoxifen.

• ~2–3%: Bone density loss/yr (placeholder text)
• ~50%: Arthralgia incidence (placeholder text)
• Aromatase block: Mechanism (near-total suppression)
• Elevated: Fracture risk (placeholder text)

Bone density effect

Placeholder: estrogen loss accelerates osteoclast activity and bone loss.

Joint pain effect

Placeholder: arthralgia and stiffness are common, dose-duration linked.

Placeholder: bone and joint risk climb steadily across the therapy years.

Matching the Drug to the Patient

Placeholder: individual history shifts which side-effect profile is safer.

• Favors AI: Clot history (placeholder text)
• Favors AI: Endometrial concern (placeholder text)
• Favors SERM: Osteoporosis risk (placeholder text)
• Favors SERM: Joint disease (placeholder text)

Weighing personal history

Placeholder: prior clots or uterine issues steer away from tamoxifen.

Bone and joint considerations

Placeholder: pre-existing bone or joint disease steers away from AI.

A Personalized, Sometimes Sequential, Choice

Placeholder: menopausal status and risk factors together guide final selection.

• Common: Sequential switching (placeholder text)
• Key input: Menopausal status (placeholder text)
• Recommended: Shared decision (placeholder text)
• 5–10 yrs: Course length (placeholder text)

Putting it together

Placeholder: profile, status, and history combine into one plan.

Placeholder: many patients switch drugs mid-course to balance risks.